You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
盤龍藥業(002864.SZ):盤龍七片基於基藥准入的基本條件及所需的研究資料,公司現已全面佈局完成
格隆匯 03-16 22:17

格隆匯3月16日丨盤龍藥業(002864.SZ)於2023年3月14日14:00-15:00接受機構調研時表示,盤龍七片作為獨家醫保甲類品種,公司在前幾年已經開始謀劃和佈局升級產品的循證醫學證據鏈條。國家基藥的遴選有幾個原則,其一是優先從醫保甲類目錄中增補基藥品種;其二是在有效性方面,公司已經做了大量的研究,發表了140餘篇盤龍七片的研究論文,在循證高等級的研究方法下,公司開展了盤龍七片的RCT研究;其三是在安全性方面,公司依託中國中醫科學院中藥研究所,由首席研究員林娜教授團隊開展盤龍七片的藥理機制,同時也開展了系統的安全性評價實驗;此外公司也開展了盤龍七片的有效成分羣的研究。目前盤龍七片的循證醫學等級已經達到較高水平,已經進入四部指南、兩本教材、兩個專家共識及一本臨牀路徑釋義,分別被列為推薦用藥,連續四年被評為中國家庭常備風濕骨病用藥上榜品牌產品。因此盤龍七片基於基藥准入的基本條件以及所需的研究資料,公司現已經全面佈局完成。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account